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The hallmark of Parkinson Disease (PD) is the degeneration of dopaminergic neurons in the
substantia nigra pars compacta (SNc) and the consequent striatal dopamine (DA) deficiency,
although it is well recognized that neurodegeneration in PD goes beyond the SNc. Major advances
have occurred in recent years on the molecular and pathophysiological basis of PD, however
there remain many questions and unknowns regarding SNc cells vulnerability, and the exact
significance of Lewy bodies and alpha-synuclein (α-syn) aggregation process regarding disease
onset and progression. This Research Topic discuss the etiopathogenesis of PD, presenting a
series of papers that provide up-to-date, state-of-the-art information on molecular and cellular
mechanisms involved in the neurodegeneration process, neuroimmune pathways, the role of
functional and anatomical organization of the basal ganglia as a factor of neuronal vulnerability, the
possibility that PD is a prion disease and the cellular response to α-syn aggregation. Understanding
the mechanisms underlying vulnerability of dopaminergic midbrain neurons and how pathology
becomes widespread are primary objectives of basic and clinical research in PD.
Are dopaminergic and other neurons dying by the same pathogenic mechanisms? Do they all
die to the same extent or at the same rate? What are the molecular determinants of susceptibility to
the disease? To gain insights into these questions, researchers mainly rely in animal models. Blesa
and Przedborski (2014) provide a summary of the current knowledge of in vivo models of PD.
Whereas PD can be sporadic, genetic or possibly related with toxic/infectious agents, a differential
pattern of cell loss among midbrain dopaminergic neurons is observed regardless of disease
etiology suggesting that differential dopaminergic neuron vulnerability does not depend on the
factor triggering PD “per se” but on intrinsic properties of these specific cell groups. Here, Brichta
and Greengard (2014) provides an update review on the molecular basis underlying differential
vulnerability of midbrain dopaminergic neurons in PD. For example, for many years many studies
have suggested calbindin (CB) as a marker to distinguish between midbrain dopaminergic neurons
with different susceptibility to degeneration in PD. Although CB dopaminergic neurons seem to be
less prone to MPTP-induced degeneration, Dopeso-Reyes et al. (2014) clearly demonstrated that
these neurons are not giving rise to nigro-striatal projections and indeed CB-ir/TH-ir neurons only
originate nigro-extrastriatal projections. This data sustain the presence of a potential imbalance
between the nigro-striatal and nigroextrastriatal systems in advanced diseases states. Also, Afonso-
Oramas et al. (2014) revealed that midbrain dopaminergic axons are in close apposition to striatal
vessels and perivascular astrocytes in rats and monkeys. The relative weight of this “vascular
component” within the meso-striatal pathway suggests a role in the pathophysiology of PD.
Aging is another major risk factor for developing PD. Rodriguez et al. (2014) reviewed
similarities between neurodegeneration in PD and aging. The progressive course of aging and
PD could be induced by the same multi-factorial etiology, including astrocytic and microglia
alterations, anomalous action of different proteins, mitochondrial disturbances, alterations of the
mitophagy or the ubiquitin-proteasome system and oxidative stress. Proteins involved in PD such
as α-syn, PINK1 or DJ-1, are also involved in aging. All these mechanisms of degeneration are
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review here giving an update of the classical pathways, the
biochemical and molecular events that mediate DA neuronal
vulnerability, and the role of PD-associated gene products in
modulating cellular responses to oxidative stress (Blesa et al.,
2015). Additionally, Labandeira-García et al. (2014) discuss
the role of renin-angiotensin system in oxidative stress, aging
and inflammation in the nigrostriatal dopaminergic system.
Inflammation is indeed a major characteristic feature of the
SNc in PD mainly as a consequence of neuronal death.
Herrero et al. (2015) review the role of inflammation and
glucocorticoids in PD while Cebrián et al. (2014) review the
neuronal MHC-I expression in the SNc and its implications in
synaptic function, axonal regeneration in PD and other brain
diseases.
The dopaminergic neurons of the SNc project primarily to
the striatum, but also provide significant innervation of other
basal ganglia nuclei and the thalamus. Villalba et al. (2015)
discuss evidence for synaptic glutamatergic dysfunction and
pathology of cortical and thalamic inputs to the striatum and
subthalamic nucleus in models of PD. The altered neuronal
firing activity of the basal ganglia and other nuclei contribute
largely to parkinsonisms. Galvan et al. (2015) reviewed the
current knowledge of the electrophysiologic changes at the single
cell level, the level of local populations of neural elements,
and the entire basal ganglia-thalamocortical network in PD,
and discuss the possible use of this information to optimize
treatment approaches. Neuroprotection by endogenous glial
cell-derived neurotrophic factor (GDNF) stimulation has been
suggested as one of the potential preventive therapies in PD
for many years. In this issue d’Anglemont de Tassigny et al.
(2015) summarize current knowledge on brain GDNF delivery,
homeostasis, and its effects on SNc neurons and discuss
the therapeutic potential of endogenous GDNF stimulation
in PD.
Formation and accumulation of misfolded α-syn aggregates
are a central and very hot topic of PD research currently. Several
authors review and discuss here the importance of this protein,
it’s role in different cellular domains (Guardia-Laguarta et al.,
2015), the pathophysiological mechanisms connecting α-syn and
lysosomal dysfunction in neuronal cell death (Bourdenx et al.,
2014), how this protein can undergo a toxic conformational
change, spread from cell to cell and from region to region, and
initiate the formation of aggregates (Recasens and Dehay, 2014),
and its possible relation to other neurodegenerative diseases like
progressive supranuclear palsy (Erro Aguirre et al., 2015).
While all the features summarized above play a significant
role in nigro-striatal neurodegeneration, it is unlikely that
the origin of neurodegeneration in PD could be tight to a
single pathogenic mechanism, hence the importance of defining
markers and features of neuronal vulnerability. Obeso’s group
introduces here the interesting hypothesis that Parkinson’s
disease could be related and ultimately be the consequence of
human multi-tasking behavior (Hernandez et al., 2015). Thus,
the caudal region of the striatum has been associated with
habitual behavior, consequently the differential loss of DA from
this region provides the pathophysiological substrate for the
early impairment of automatic movements (walking, writing. . . )
and probably increased functional demand during multiple and
simultaneous tasks performance.
In sum, understanding the mechanisms responsible for
intrinsic SNc neuronal vulnerability is mandatory to progress in
stopping neurodegeneration in PD. We trust that this Research
Topic will spark new ideas and foster further advances in PD.
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